Previous Close | 0.3550 |
Open | 0.3500 |
Bid | 0.3400 x 0 |
Ask | 0.3500 x 0 |
Day's Range | 0.3300 - 0.3500 |
52 Week Range | 0.3300 - 0.6900 |
Volume | |
Avg. Volume | 38,572 |
Market Cap | 48.647M |
Beta (5Y Monthly) | 0.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0510 |
Earnings Date | Feb 08, 2023 - Feb 13, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Sept 02, 1999 |
1y Target Est | 1.13 |
MISSISSAUGA, Ontario, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter ended December 31, 2022 (“Q1”), a period in which reduced sales across two major product lines resulted in the first quarterly net loss in two years. Microbix remains well-capitalized and is targeting to continue increasing sales of its testing-related medical devices and ingredients, the
QAPs for HPV Test Verification within Cervical Cancer Screening ProgramMISSISSAUGA, Ontario, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it will be presenting results of its collaboration with the Microbiology Laboratory of the Queen Elizabeth Hospital of Health PEI (“Health PEI”), in support of provincial adoption of molecular diagnostic (“MDx”) screening for Human Papilloma
Driven by Customer Requests, Mpox Test Control Now AvailableMISSISSAUGA, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces that it is launching a new quality assessment product (“QAP™”) to support molecular diagnostic (“MDx”) testing for the Non-Variola Orthopoxvirus (“Mpox”), the cause of the cutaneous infection colloquially-known as “Monkeypox.” From traditional low-level inc